Literature DB >> 21412085

Early response of hepatic malignancies to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy.

Susanne Bonekamp1, Jialin Shen, Nouha Salibi, Hong C Lai, Jeff Geschwind, Ihab R Kamel.   

Abstract

PURPOSE: The objective of our study was to determine the usefulness of the diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy (H-MRS) of hepatic malignancies for the assessment of response to locoregional treatment.
METHODS: Forty-four patients (29 men; mean age, 58 years) with hepatic malignancies were treated locally. Magnetic resonance imaging examinations obtained before and at 1 and 6 months after transarterial chemoembolization were analyzed retrospectively. Imaging criteria included change in tumor size, percentage of enhancement in the arterial and portal venous phases, diffusion-weighted magnetic resonance imaging apparent diffusion coefficients, and choline concentration by quantitative H-MRS. Response to treatment was grouped according to RECIST (Response Evaluation Criteria in Solid Tumors) and European Association for the Study of the Liver (EASL) criteria based on magnetic resonance imaging at 6 months after treatment. Statistical analysis used paired t test, Fisher exact test, and univariate and multivariate Cox proportional hazards models.
RESULTS: Before treatment, the median tumor diameter was 6 cm; at 6 months after treatment, median tumor diameter was 5.1 cm. According to RECIST and EASL, 66% of the patients achieved partial response, 31% had stable disease, and 3% of the patients showed progressive disease. One month after transarterial chemoembolization, apparent diffusion coefficient increased (P < 0.14), and mean choline concentration of the tumors decreased (P < 0.008).
CONCLUSIONS: Diffusion-weighted imaging and hepatic choline levels by H-MRS could predict response to locoregional therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21412085      PMCID: PMC4332789          DOI: 10.1097/RCT.0b013e3182004bfb

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  34 in total

1.  In vivo 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization.

Authors:  Bin Wu; Wei-Jun Peng; Pei-Jun Wang; Ya-Jia Gu; Wen-Tao Li; Liang-Pin Zhou; Feng Tang; Guo-Ming Zhong
Journal:  Chin Med Sci J       Date:  2006-12

2.  The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.

Authors:  Ihab R Kamel; David A Bluemke; John Eng; Eleni Liapi; Wells Messersmith; Diane K Reyes; Jean-Francois H Geschwind
Journal:  J Vasc Interv Radiol       Date:  2006-03       Impact factor: 3.464

3.  Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization.

Authors:  Jie Deng; Frank H Miller; Thomas K Rhee; Kent T Sato; Mary F Mulcahy; Laura M Kulik; Riad Salem; Reed A Omary; Andrew C Larson
Journal:  J Vasc Interv Radiol       Date:  2006-07       Impact factor: 3.464

4.  Non-resective ablation and liver transplantation in patients with cirrhosis and hepatocellular carcinoma (HCC): safety and efficacy.

Authors:  D Maluf; R A Fisher; T Maroney; A Cotterell; A Fulcher; J Tisnado; M Contos; V Luketic; R Stravitz; M Shiffman; R Sterling; M Posner
Journal:  Am J Transplant       Date:  2003-03       Impact factor: 8.086

5.  Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging.

Authors:  Nagaaki Marugami; Toshihiro Tanaka; Satoru Kitano; Shinji Hirohashi; Hideyuki Nishiofuku; Aki Takahashi; Hiroshi Sakaguchi; Masaki Matsuoka; Toshio Otsuji; Junko Takahama; Wataru Higashiura; Kimihiko Kichikawa
Journal:  Cardiovasc Intervent Radiol       Date:  2009-02-24       Impact factor: 2.740

6.  Modern diagnosis and management of hepatocellular carcinoma.

Authors:  Jorge A Marrero; Theodore Welling
Journal:  Clin Liver Dis       Date:  2009-05       Impact factor: 6.126

7.  Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization.

Authors:  Eleni Liapi; Jean-Francois Geschwind; Josephina A Vossen; Manon Buijs; Christos S Georgiades; David A Bluemke; Ihab R Kamel
Journal:  AJR Am J Roentgenol       Date:  2008-01       Impact factor: 3.959

8.  Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization.

Authors:  Josephina A Vossen; Ihab R Kamel; Manon Buijs; Eleni Liapi; Christos S Georgiades; Kelvin Hong; Jean-Francois H Geschwind
Journal:  J Comput Assist Tomogr       Date:  2008 May-Jun       Impact factor: 1.826

9.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

Authors:  Alejandro Forner; Carmen Ayuso; María Varela; Jordi Rimola; Amelia J Hessheimer; Carlos Rodriguez de Lope; María Reig; Luís Bianchi; Josep M Llovet; Jordi Bruix
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

10.  Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma.

Authors:  Zheng Yuan; Xiao-Dan Ye; Sheng Dong; Li-Chao Xu; Xue-Yuan Xu; Shi-Yuan Liu; Xiang-Sheng Xiao
Journal:  Eur J Radiol       Date:  2009-06-18       Impact factor: 3.528

View more
  6 in total

Review 1.  Advanced imaging techniques in the therapeutic response of transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Ke Yang; Xiao-Ming Zhang; Lin Yang; Hao Xu; Juan Peng
Journal:  World J Gastroenterol       Date:  2016-05-28       Impact factor: 5.742

Review 2.  Musculoskeletal tumors: how to use anatomic, functional, and metabolic MR techniques.

Authors:  Laura M Fayad; Michael A Jacobs; Xin Wang; John A Carrino; David A Bluemke
Journal:  Radiology       Date:  2012-11       Impact factor: 11.105

Review 3.  Diffusion MRI in early cancer therapeutic response assessment.

Authors:  C J Galbán; B A Hoff; T L Chenevert; B D Ross
Journal:  NMR Biomed       Date:  2016-01-15       Impact factor: 4.044

4.  Carbogen gas-challenge blood oxygen level-dependent magnetic resonance imaging in hepatocellular carcinoma: Initial results.

Authors:  Long Jiang Zhang; Zhuoli Zhang; Jian Xu; Ning Jin; Song Luo; Andrew C Larson; Guang Ming Lu
Journal:  Oncol Lett       Date:  2015-07-23       Impact factor: 2.967

5.  Diagnostic value of 3.0T (1)H MRS with choline-containing compounds ratio (∆CCC) in primary malignant hepatic tumors.

Authors:  Li Zhang; Xinming Zhao; Han Ouyang; Shuang Wang; Chunwu Zhou
Journal:  Cancer Imaging       Date:  2016-08-22       Impact factor: 3.909

6.  Hypo-Vascular Liver Metastases Treated with Transarterial chemoembolization: Assessment of Early Response by Volumetric Contrast-Enhanced and Diffusion-Weighted Magnetic Resonance Imaging.

Authors:  Fatemeh Sobhani; Chunmiao Xu; Emi Murano; Li Pan; Neda Rastegar; Ihab R Kamel
Journal:  Transl Oncol       Date:  2016-08       Impact factor: 4.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.